Pronounced: gee-yan bah-ray sin-droam
Guillain-Barré syndrome is a rare condition that causes the immune system to attack the nerves outside of the brain and spinal cord. It is characterized by numbness, tingling, weakness, or paralysis in the legs, arms, breathing muscles, and face. It can affect all ages.
Copyright © Nucleus Medical Media, Inc.
The exact cause of Guillain-Barré syndrome is unknown. However, in about 70% of patients, a recent infection or surgery is a trigger to an autoimmune response. This autoimmune response attacks the peripheral nerves, leading to weakness and a loss of sensation.
A risk factor is something that increases your chance of getting a disease or condition. Risk factors for Guillain-Barré syndrome may include:
The first symptoms of Guillain-Barré syndrome include:
Symptoms may develop over a period of hours, days, or weeks. They will vary in severity from minimal to total paralysis including respiratory weakness. The symptoms grow progressively worse. Most people experience the greatest weakness during the second or third week.
Related complications include:
Most patients recover fully, but as many as 25% will have some residual symptoms. 5%-10% have permanent, disabling deficits. For 5% the condition is fatal.
Your doctor will ask about your symptoms and medical history, and perform a physical exam. Diagnosis is dependant on the physical exam and history, cerebrospinal fluid findings, and nerve conduction studies .
You may have a lumbar puncture, also called a spinal tap . For this test, a needle is inserted into your lower back to remove a sample of cerebrospinal fluid for testing. If high levels of protein are detected, and there is no infection, this is an indication that you may have Guillain-Barré syndrome. Electrodiagnostic studies are usually done, which test the electrical conduction in the peripheral nerves and help differentiate Guillain-Barré from other disorders with similar symptoms.
Treatment aims to reduce the body’s autoimmune response and decrease complications that result from immobility. Hospitalization is important because symptoms may rapidly become more severe, including respiratory failure, cardiac arrhythmias , and blood pressure instability. Most patients need to be in the hospital for a while. Common treatments include:
During plasmapheresis , blood is removed from your body and passed through a machine that separates blood cells. The separated cells are then returned to your body with new plasma. This procedure may help shorten the course and severity of Guillain-Barré syndrome.
Intravenous infusion with immunoglobulin (IVIg) may help reduce the severity of a Guillain-Barré attack. Immunoglobulins are proteins that are naturally produced by the body’s immune system.
In 30% of cases, muscles necessary for breathing become paralyzed. This is treated with immediate emergency support from a mechanical ventilator.
Your doctor may prescribe medication to reduce the pain. These may include nonsteroidal anti-inflammatory drugs, gabapentin, carbamezepine, or narcotic analgesics.
If you are diagnosed with Guillain-Barré syndrome, follow your doctor's instructions .
Guillain-Barré Syndrome Foundation International
National Institute of Neurological Disorders and Stroke
Canadian Institute for Health Information
Amyotrophic lateral sclerosis. EBSCO Publishing DynaMed website. Available at: Available at: http://www.ebscohost.com/dynamed . Updated January 31, 2008. Accessed February 23, 2008.
Bradley WG, Daroff RB. Neurology in Clinical Practice . Philadelphia, PA: Butterworth Heinemann Publishing; 2004.
Brown B Amyotrophic lateral sclerosis. In: Gilman S, ed. MedLink Neurology. San Diego, CA: MedLink Corporation. Available at: http://www.medlink.com . Accessed February 23, 2008.
Goetz S. Acute inflammatory demyelinating polyradiculoneuropathy. In: Clinical Neurology. 3rd ed. Philadelphia, PA: Saunders; 2007.
National Institute of Neurological Disorders and Stroke website. Available at: http://www.ninds.nih.gov .
Textbook of Clinical Neurology . WB Saunders Company; 1999.
Vucic S, Kiernan MC, Cornblath DR. Guilainn-Barre: an update. J Clinical Neuroscience . 2009;16(6):733-741.
Last reviewed September 2013 by Rimas Lukas, MD; Michael Woods, MD
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © 2012 EBSCO Publishing All rights reserved.
What can we help you find?close ×